Dr Goede speaks with ecancer at EHA 23 about the use of CD20 targeted antibody obinutuzumab compared to rituximab in combination with chlorambucil chemotherapy.

He describes the 3 arms of the trial, which found the combination of obinutuzumab and chemotherapy progression free survival and overall survival compared to rituximab, and considers future CD20 based combinations and therapies.

For more on these findings, watch his presentation of the results at a press session here.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.